HSA Priority Review Route 1 and Route 2 for Full Evaluations

1. Key takeaways

HSA’s Priority Review channel is not an independent fifth route but a paid acceleration option that applies only to the Full route, covering Class B/C/D. It has two lanes: Route 1 is for high-impact products that fill a treatment gap or represent a significant improvement over existing options, and must target HSA’s designated priority health areas (cancer, diabetes, cardiovascular disease, ophthalmic disease, infectious disease); Route 2 is for other Full-route products that do not meet the Route 1 conditions but still want the paid fast lane. The acceleration is roughly 35%, and the premium is explicit.

• Route 1 and Route 2 deliver identical timelines; the price difference is purely an eligibility premium, so the real decision is whether the product can substantiate the priority-area and treatment-gap argument.
• The saving converts to 56 working days for Class B, 77 for Class C and 108 for Class D.
• Expressed as a cost per working day saved, the Route 1 premium is low enough that for most products with genuine market demand the acceleration is worth buying.
• Priority Review improves speed, not eligibility: it cannot make an Abridged-ineligible product qualify, and it does not relax evidence requirements.
• The stop-clock rule still applies, so poor dossier quality dilutes the value of paying for acceleration.

2. Legal basis

The Priority Review option is described in GN-15 together with the route definitions, and the statutory foundation is Part VII of the Health Products Act 2007. The conditions for Route 1 and Route 2 are consolidated from industry sources and the HSA official text prevails. Fees and timelines come from the official HSA fees page, and the SGD 560 application fee is charged separately on top of every figure in the table.

Fee and timeline comparison (SGD 560 application fee charged separately)

3. Expert insights

Insight one: Route 1 and Route 2 have identical timelines; the price gap is only an eligibility premium.

The data show that for Class B, Route 1 (SGD 4,420) and Route 2 (SGD 5,660) both take 104 working days, a price gap of SGD 1,240; Class C is 143 working days on both, with a gap of SGD 2,000; Class D is 202 working days on both, with a gap of SGD 3,900. The two lanes speed things up exactly the same; Route 1 is simply the cheaper ticket. The real decision, therefore, is whether your product can substantiate the combination of a priority area plus a treatment gap or significant improvement.

Insight two: the acceleration is about 35%, and it pays to see what that means in days.

• Class B: 160 to 104, saving 56 working days
• Class C: 220 to 143, saving 77 working days
• Class D: 310 to 202, saving 108 working days

Insight three: whether it is worth it depends on the commercial value of each day of launch delay.

Our judging framework is simple: divide the premium by the working days saved to get the acceleration cost per working day, and compare that with the product’s daily gross margin or market window value.

• Class B Route 1: premium of SGD 520 divided by 56 working days, about SGD 9.3 per working day
• Class C Route 1: premium of SGD 750 divided by 77 working days, about SGD 9.7 per working day
• Class D Route 1: premium of SGD 1,600 divided by 108 working days, about SGD 14.8 per working day

Taking Class B as an example, less than 10 SGD per day buys a day of earlier market entry, which for the vast majority of products with real market demand is a bargain. (The above is our practical estimate, not an official HSA metric.)

Insight four: Priority Review does not improve eligibility, only speed.

It cannot turn a product that fails the Abridged criteria into one that meets them. If the product holds no Reference Agency approval at all, Priority Review simply accelerates the journey within the Full route and changes nothing about the evidence requirements. Do not mistake it for an antidote to eligibility problems.

Insight five: the stop-clock rule applies equally here.

Priority Review shortens HSA’s evaluation clock, but the stop-clock time spent answering queries is unaffected. If the technical dossier is weak and query rounds are many, the meaning of the acceleration is diluted. Our advice: make sure the dossier is right the first time before buying speed.

4. Practical recommendations

• Strive for Route 1 first: build the priority-area plus treatment-gap or significant-improvement argument first, saving SGD 1,240 to 3,900.
• Decide using the cost per working day saved: do not judge expensiveness by feel.
• Put dossier quality ahead of paid acceleration: the stop-clock period is not affected by acceleration.
• Tie acceleration to the launch window: if the product is racing a tender, a trade show or a competitor’s gap, the commercial value of acceleration rises significantly.
• Do not abandon the effort to obtain a Reference Agency approval: Abridged for Class D (SGD 6,250 / 220 working days) still beats Full + Priority Route 1 (SGD 13,600 / 202 working days) on fee, with only a slightly longer timeline.

5. Verification checklist

• □ It has been confirmed that the Full route is being used (Priority Review applies to Full only)
• □ It has been argued whether the product falls within HSA’s five priority health areas
• □ Evidence material for the treatment gap or significant improvement has been prepared
• □ The cost per working day saved has been calculated and compared with commercial value
• □ Technical dossier quality has been confirmed as sufficient to reduce query rounds
• □ The total cost of Abridged versus Full + Priority has been compared

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com